Makucell launches anti-aging skin care brand with innovative new technology
Makucell — a regenerative biotechnology company that develops, manufactures and distributes anti-aging skin care — has unveiled its new Renewnt brand. The product line uses a proprietary ingredient known as Asymmtate, which the company said energizes the skin’s stem cells, encouraging youthful cell behavior for firmer and smoother skin.
Asymmtate technology was developed at University of Southern California’s Keck School of Medicine and transferred to Makucell’s Renewnt skin care line. The technology encourages optimal signaling in the body’s Wnt signal pathway, thereby stimulating the skin stem cells to begin the process leading to keratinocytes, fibroblasts and other dermal cells, which produce collagen, elastic tissue and substances in the supporting skin matrix.
According to the company, Renewnt products:
Penetrate into viable skin;
Are not irritating or sensitizing;
Show measurable up-regulation of genes that express skin structural proteins with simultaneous down-regulation of inflammatory genes in gene expression analysis; and
Perform well in clinical studies. Skin shows smoothing, plumping and an improvement in texture after as little as four weeks.
“Makucell is committed to supporting our claims with results from controlled, blinded studies,” explains Dr. Mark Dahl, Makucell chief medical officer and former president of the American Academy of Dermatology. “We conducted standard industry safety tests, and the results were universally positive; Renewnt products were well tolerated with no adverse effects or safety issues. A combination of clinical trials and in vitro gene expression studies from treated biopsied skin continues to corroborate the aesthetic effects noted in the clinic.”
Makucell’s current Renewnt skin care products include:
Renewnt for Hydration, a day and night facial moisturizer for a more youthful-looking appearance;
Renewnt for Strength, for the dry, thinning skin on hands and forearms to seal in moisture, repair the signs of aging and restore the essential skin barrier;
Renewnt for Firmness, a neck and décolletage cream hydrates and improves elasticity, reduces wrinkles and roughness, and visibly increases firmness; and
Renewnt for Brightness, a serum to address irregular skin pigmentation and sun damage to lighten and even skin color.
Pringles offers free speaker can with purchase of four Pringles cans
Pringles is celebrating summer by giving away portable speakers that can be brought along to the beach, camping, picnics, on boats, and summer concerts and festivals. From May 15 through Oct. 31, Pringles-lovers can send in the original receipt from any four traditional-sized Pringles cans, and a portable Pringles Speaker will be mailed to them.
The speaker fits on top of an empty Pringles can and attaches to any personal MP3 player or similar music device, allowing consumers to carry it anywhere.
The potato chip company teamed with Perez Hilton, celebrity blogger and avid music lover, and named him the brand’s official summer ambassador. "During the summer, I love to hike and stay active, and what’s better than hanging out in the park with friends and family?" Hilton said. "The Pringles Speaker Can is a perfect way to share my favorite summer songs and stay on track with my favorite up-and-coming musicians."
Pringles crisps are available at U.S. mass grocery, club, dollar and drug retailers. For more info or to download the free Pringles Speaker Can redemption form, visit Pringles.com/current-promotions.
Alexza resubmits Adasuve for regulatory review
MOUNTAIN VIEW, Calif. — A drug maker has resubmitted its new drug application to the Food and Drug Administration for an acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza Pharmaceuticals said it received a complete response letter for Adasuve last month from the regulatory agency. The CRL outlined the FDA’s concerns about Alexza’s manufacturing facility and the drug’s draft product labeling. Alexza said it believes it has addressed these concerns in its resubmitted application.
In the coming weeks, Alexza expects to hear from the FDA regarding the completeness of the resubmitted NDA, the classification of the resubmission (Class 1 or Class 2) and what the new Prescription Drug User Fee Act goal date will be.